Atezolizumab and Bevacizumab in Patients With Recurrent or Metastatic Squamous-cell Carcinoma of the Head and Neck
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
This proof-of-concept study aims to assess the clinical and biological effects of
Atezolizumab combined with Bevacizumab in advanced previously treated squamous-cell carcinoma
of the head and neck (HNSCC).